G. Junge

2.9k total citations
79 papers, 1.5k citations indexed

About

G. Junge is a scholar working on Surgery, Transplantation and Immunology. According to data from OpenAlex, G. Junge has authored 79 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Surgery, 33 papers in Transplantation and 26 papers in Immunology. Recurrent topics in G. Junge's work include Renal Transplantation Outcomes and Treatments (33 papers), Organ Transplantation Techniques and Outcomes (25 papers) and Complement system in diseases (17 papers). G. Junge is often cited by papers focused on Renal Transplantation Outcomes and Treatments (33 papers), Organ Transplantation Techniques and Outcomes (25 papers) and Complement system in diseases (17 papers). G. Junge collaborates with scholars based in Switzerland, United States and Germany. G. Junge's co-authors include Eugen Feist, Gaohong Dong, John J. Fung, Paolo De Simone, Lutz Fischer, Luciano De Carlis, Faouzi Saliba, Christophe Duvoux, Herold J. Metselaar and Sven Jonas and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

G. Junge

75 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Junge Switzerland	19	661	631	401	372	324	79	1.5k
Stéphan Busque United States	27	1.1k 1.6×	1.4k 2.2×	499 1.2×	281 0.8×	279 0.9×	69	2.6k
Nina Tolkoff‐Rubin United States	18	432 0.7×	613 1.0×	287 0.7×	215 0.6×	155 0.5×	29	1.2k
Fabrizio Fop Italy	22	539 0.8×	365 0.6×	101 0.3×	241 0.6×	157 0.5×	81	1.4k
David A. Laskow United States	21	753 1.1×	1.1k 1.8×	265 0.7×	111 0.3×	144 0.4×	50	2.1k
Antonio Schena Italy	18	464 0.7×	716 1.1×	188 0.5×	153 0.4×	120 0.4×	43	1.8k
Maria Scolari Italy	18	405 0.6×	404 0.6×	199 0.5×	134 0.4×	77 0.2×	77	1.4k
Phuong‐Thu T. Pham United States	16	378 0.6×	392 0.6×	138 0.3×	110 0.3×	143 0.4×	31	1.0k
Joseph Kahwaji United States	20	701 1.1×	1.3k 2.1×	544 1.4×	56 0.2×	193 0.6×	43	1.8k
F. Vincenti United States	11	512 0.8×	807 1.3×	363 0.9×	81 0.2×	55 0.2×	54	1.6k
Nils Lachmann Germany	23	968 1.5×	1.5k 2.4×	512 1.3×	106 0.3×	93 0.3×	73	1.9k

Countries citing papers authored by G. Junge

Since Specialization

Citations

This map shows the geographic impact of G. Junge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Junge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Junge more than expected).

Fields of papers citing papers by G. Junge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Junge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Junge. The network helps show where G. Junge may publish in the future.

Co-authorship network of co-authors of G. Junge

This figure shows the co-authorship network connecting the top 25 collaborators of G. Junge. A scholar is included among the top collaborators of G. Junge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Junge. G. Junge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dörner, Thomas, Simon Bowman, Robert I. Fox, et al.. (2024). Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study. Arthritis & Rheumatology. 77(5). 560–570. 3 indexed citations

Voltz, Emilie, Ülrike Sommer, Elaine Tritto, et al.. (2024). First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. Clinical and Translational Science. 17(5). e13789–e13789. 27 indexed citations

Nester, Carla, Ute Eisenberger, Alexandre Karras, et al.. (2024). Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy. Kidney International Reports. 10(2). 432–446. 2 indexed citations

Schmouder, Robert, G. Junge, Prasanna Kumar Nidamarthy, & Kenneth Kulmatycki. (2023). #4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations

Schmouder, Robert, G. Junge, Prasanna Kumar Nidamarthy, & Kenneth Kulmatycki. (2023). A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101). Blood. 142(Supplement 1). 4096–4096. 2 indexed citations

Schmouder, Robert, et al.. (2023). #4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations

Schmouder, Robert, G. Junge, Prasanna Kumar Nidamarthy, & Kenneth Kulmatycki. (2023). #3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN. Nephrology Dialysis Transplantation. 38(Supplement_1). 3 indexed citations

Risitano, Antonio M., Régis Peffault de Latour, Jun Ho Jang, et al.. (2023). Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 142(Supplement 1). 5643–5643. 1 indexed citations

Chapman, William C., Robert S. Brown, Kenneth D. Chavin, et al.. (2016). Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients. Transplantation. 101(2). 341–349. 9 indexed citations

10.

Simone, Paolo De, Luciano De Carlis, Frederik Nevens, et al.. (2014). The H2304E1 Study: Efficacy and Safety of Everolimus With Reduced Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients at 36 Months.. Liver Transplantation. 20.

11.

Fukagawa, Masafumi, et al.. (2013). Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clinical and Experimental Nephrology. 18(1). 135–143. 12 indexed citations

12.

Fung, John J., Frederik Nevens, Luciano De Carlis, et al.. (2012). Everolimus with early reduction or elimination of tacrolimus in 719 de novo liver transplant recipients - 12 month efficacy and safety results from the H2304 study. American Journal of Transplantation. 12. 28–28. 1 indexed citations

13.

Simone, Paolo De, Frederik Nevens, Luciano De Carlis, et al.. (2012). Renal function with everolimus and reduced tacrolimus in de novo liver transplant recipients: 12 month results of the H2304 trial. O-17. Liver Transplantation. 18. 5 indexed citations

14.

Simone, Paolo De, Frederik Nevens, Luciano De Carlis, et al.. (2012). Evolution of Renal Function with Early Everolimus-Facilitated Reduction or Elimination of Tacrolimus in 719 De Novo Liver Transplant Recipients: 12 Month Data of the H2304 Study. American Journal of Transplantation. 12(3). 238–238. 1 indexed citations

15.

Saliba, Faouzi, Paolo De Simone, Frederik Nevens, et al.. (2011). Efficacy and safety of everolimus with early reduction or elimination of tacrolimus in 719 de novo liver transplant recipients: 12 month results of a phase iii, randomized, controlled study. Hepatology. 54. 1 indexed citations

16.

Filipponi, Franco, et al.. (2010). Everolimus in De Novo Liver Transplant Recipients To Either Minimize or Eliminate Tacrolimus - Study Design and Update. Liver Transplantation. 16(6). 1 indexed citations

17.

Köhler, Sven, Andreas Pascher, G. Junge, et al.. (2008). Graft versus host disease after liver transplantation – a single center experience and review of literature. Transplant International. 21(5). 441–451. 41 indexed citations

18.

Junge, G., Stefan G. Tullius, Johann Pratschke, et al.. (2005). The Influence of Late Acute Rejection Episodes on Long-Term Graft Outcome After Liver Transplantation. Transplantation Proceedings. 37(4). 1716–1717. 9 indexed citations

19.

Pfitzmann, Robert, J Klupp, Jan M. Langrehr, et al.. (2002). Mycophenolate mofetil for treatment of ongoing or chronic rejections after liver transplantation. Transplantation Proceedings. 34(7). 2938–2939. 2 indexed citations

20.

Langrehr, Jan M., J Klupp, G. Junge, et al.. (2001). Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. Transplantation Proceedings. 33(3). 2330–2331. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact